Congresswoman Renee Ellmers Discusses the Cancer Patient Protection Act of 2013

Video

Congresswoman Renee Ellmers (R-NC-02), U.S. House of Representatives, discusses the importance of the Cancer Patient Protection Act of 2013 (H.R. 1416).

Congresswoman Renee Ellmers (R-NC-02), U.S. House of Representatives, discusses the importance of the Cancer Patient Protection Act of 2013 (H.R. 1416).

Ellmers says this is a sensible bill that takes care of Medicare patients with cancer in relation to the sequester that negatively affected physician-administered drugs under part B of the Medicare program. Currently, oncologists and other physicians that purchase expensive drugs to care for their patients find themselves in a difficult situation. Ellmers says cancer patients on Medicare are most vulnerable.

Ellmers says she has been working hard on this bill for over a year and is determined​ to change the current situation and ensure that care can be provided in community cancer centers. If patients with cancer are unable to continue to receive care at a center they feel comfortable with, they may have to travel great distances to another cancer center. This could both interrupt care and make it more expensive for an individual patient.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD